GC Therapeutics
Mark Zaki, MD, MBA, currently serves as a Specialist in Clinical and Risk Excellence at McKinsey & Company since September 2024, while also completing a residency in Neurosurgery at Michigan Medicine since June 2021. Prior experience includes a role as a Medical Analyst at GC Therapeutics from April 2020 to August 2024 and an internship in the Growth Department at Viz.ai during June 2020 to August 2020. Mark Zaki earned an MBA from Harvard Business School (2019-2021) and an MD from Harvard Medical School (2016-2021), following a dual undergraduate degree in Neuroscience (BS) and History and Philosophy of Science (BA) from the University of Pittsburgh (2012-2016), and completed a study abroad program in Natural Sciences (Biological) at the University of Cambridge in 2014-2015.
This person is not in any teams
This person is not in any offices
GC Therapeutics
1 followers
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.